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Introduction
Almost 1 in 5 female adolescents and
young women will give birth before age
20 years.1 Of the approximately 574,000
adolescent pregnancies that occur each
year in the United States, 75% are
unintended.2 Although the United States
has experienced a recent decline in teen
pregnancy,3 the rate remains higher than
the rates in many other comparable
developed nations.4 Rates of unintended
pregnancy in young women in poverty
have increased while rates in more
affluent women have declined. Racial
and ethnic disparities also exist. The
pregnancy rates among black and Latina
teens are over twice that of white teens.1
Adolescents who become pregnant, and
especially those pregnant again within 1
year of the previous pregnancy, are more
likely to subsequently experience serious
negative educational, economic, health,
and social events than are adolescent
females of the same age, race, and
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BACKGROUND: Among adolescent pregnancies, 75% are unintended. Greater use of highly-effective contraception can reduce unin-
tended pregnancy. Although multiple studies discuss adolescent contraceptive use, there is no consensus regarding the use of long-acting
reversible contraception as a first-line contraception option.
OBJECTIVE:We performed a systematic review of the medical literature to assess the continuation of long-acting reversible contraceptives
among adolescents.
STUDY DESIGN: Ovid-MEDLINE, Cochrane databases, and Embase databases were searched using key words relevant to the provision of
long-acting contraception to adolescents. Articles published from January 2002 through August 2016 were selected for inclusion based
on specific key word searches and detailed review of bibliographies. For inclusion, articles must have provided data on method
continuation, effectiveness, or satisfaction of at least 1 long-acting reversible contraceptive method in participants <25 years of age.
Duration of follow-up had to be 6 months. Long-acting reversible contraceptive methods included intrauterine devices and the eto-
nogestrel implant. Only studies in the English language were included. Guidelines, systematic reviews, and clinical reviews were examined
for additional citations and relevant points for discussion. Of 1677 articles initially identified, 90 were selected for full review. Of these, 12
articles met criteria for inclusion. All studies selected for full review were extracted by multiple reviewers; inclusion was determined by
consensus among authors. For studies with similar outcomes, forest plots of combined effect estimates were created using the random
effects model. The meta-analysis of observational studies in epidemiology guidelines were followed. Primary outcomes measured were
continuation of method at 12 months, and expulsion rates for intrauterine devices.
RESULTS: This review included 12 studies, including 6 retrospective cohort studies, 5 prospective observational studies, and 1 ran-
domized controlled trial. The 12 studies included 4886 women age<25 years: 4131 intrauterine device users and 755 implant users. The
12-month continuation of any long-acting reversible contraceptive device was 84.0% (95% confidence interval, 79.0e89.0%). Intra-
uterine device continuation was 74.0% (95% confidence interval, 61.0e87.0%) and implant continuation was 84% (95% confidence
interval, 77.0e91.0%). Among postpartum adolescents, the 12-month long-acting reversible contraceptive continuation rate was 84.0%
(95% confidence interval, 71.0e97.0%). The pooled intrauterine device expulsion rate was 8.0% (95% confidence interval, 4.0e11.0%).
CONCLUSION: Adolescents and young women have high 12-month continuation of long-acting reversible contraceptive methods. In-
trauterine devices and implants should be offered to all adolescents as first-line contraceptive options.
Key words: adolescents, birth control, contraception, implant, intrauterine device, long-acting reversible contraception, meta-analysis,
systematic review
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ethnicity who did not become pregnant.5
Inconsistent use of contraceptives, use of
less-effective methods, and nonuse of
contraceptives contribute to the high
rate of unintended pregnancy among US
adolescents.2
Greater use of highly effective
contraception can reduce unintended
pregnancy rates in this at-risk popula-
tion. Long-acting reversible contracep-
tive (LARC) methods include
intrauterine devices (IUDs) and the
etonogestrel (ENG) subdermal implant.
There are 2 general groups of IUDs
commercially available in the United
States: hormonal and nonhormonal.
The primary mechanism of the
levonorgestrel-containing IUD (LNG-
IUD) is the release of the progestin
levonorgestrel, which thickens cervical
mucus, thereby preventing fertilization.
The primary mechanism of the
nonhormonal copper-containing IUD
(Cu-IUD) is the release of copper ions
that inhibit sperm function, preventing
fertilization. The reversible method of
contraception most commonly used by
US women is the oral contraceptive
pill.6 The failure rate of combined
hormonal contraceptive methods (oral
contraceptive pill, ring, or patch) is
>20-fold higher than that of LARC
methods.7 The safety of LARC
methods is well-established and has led
to their endorsement as first-line con-
traceptive methods by the American
Congress of Obstetricians and Gyne-
cologists (ACOG)8 and the American
Academy of Pediatrics (AAP).9 In the
Selected Practice Recommendations for
Contraceptive Use, the Centers for
Disease Control and Prevention (CDC)
acknowledge that LARCs are the most
effective reversible methods and are
appropriate for adolescents and
nulliparous women.10-12 Although
multiple studies discuss continuation
of LARC methods in the adolescent
population, there is no consensus of
continuation rates for IUDs and
implants among adolescents and young
women. The objective of this system-
atic review is to provide an assessment
of the findings of the medical literature
of the use of LARC methods in young
women age <25 years. Our hypothesis
was that continuation rates for
adolescents using the IUD or implant
are high (>75%) at 1 year from
initiation.
Materials and Methods
Search strategies and data sources
We included both randomized
controlled trials (RCT) and observa-
tional trials in our review. Meta-analysis
of observational studies in epidemiology
(MOOSE) guidelines were followed.13 A
literature search was performed of the
Ovid-MEDLINE, Cochrane databases,
and Embase databases using key words
relevant to the provision of long-acting
contraception to adolescents. Because
the goal was to look at contemporary
LARCmethods, the searchwas limited to
articles published in 2002 or later. The
search was limited to English-language
articles. The full search terms and strat-
egy are shown in online supplementary
material.
Inclusion and exclusion criteria
To be included in our final analysis, ar-
ticles must have reported data on
continuation of at least 1 LARC method
among participants with at least 6
months of follow-up. While the primary
outcomewas continuation at 12months,
studies were included that have 6-month
continuation as a secondary outcome
when assessing expulsion. Included
studies must have provided actual
continuation of participants, not esti-
mated continuation. “Adolescent” is not
consistently defined by specific ages in
the medical literature, therefore we
included women24 years of age.When
a study included age groups extending
>24 years of age, the published article
must have stratified the results by age
group and must have included at least 1
cohort of at least 20 participants exclu-
sively 24 years of age. When data
were not reported for such a cohort, the
study was excluded. In addition, studies
with >30% loss to 12-month follow-up
were excluded. Studies were also
excluded if they described LARC among
special populations of adolescents
(eg, those with chronic disease such as
HIV). Studies examining postabortion
and postpartum adolescents were
included. Two investigators (J.T.D. and
D.A.K.) independently assessed titles
and abstracts for inclusion. Articles that
both of them deemed to meet inclusion
criteria were included. In cases of
disagreement, the senior author (J.F.P.)
determined whether inclusion criteria
were met.
Data extraction
Data were extracted by 2 investigators
(J.T.D. and D.A.K.) for all included
FIGURE 1
Selection of included studies in systematic review
Studies included in systematic review of adolescent use of long-acting reversible contraceptives.
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TABLE 1
Included studies evaluating use of long-acting reversible contraception among adolescent patients
Author Year Study type
Age
range, y n LARC
Follow-up,
mo Outcome Insertion timing Country Nulliparous Attrition
Godfrey et al18 2010 RCT 14e18 23 Cu-IUD
LNG-IUD
6 6 mo Continuation
Expulsion
Interval US 52% 2%
Guazzelli et al19 2010 Prospective
cohort
<20 44 Implant 12 12 mo Continuation Postpartum Brazil 0 6%
Alton et al15 2012 Retrospective
cohort
11e21 233 Cu-IUD
LNG-IUD
96 12 mo Continuation Interval US 30% NR
Rosenstock et al20 2012 Prospective
cohort
14e19 763 Cu-IUD
LNG-IUD
Implant
12 12 mo Continuation Interval, postpartum,
postabortion
US 77% 6%
Teal and Sheeder21 2012 Retrospective
cohort
14e23 136 Cu-IUD
LNG-IUD
12 12 mo Continuation
Expulsion
Postpartum US 0 14%
Tocce et al24 2012 Prospective
cohort
13e23 171 Implant 12 12 mo Continuation
6 mo Continuation
Postpartum US 0 5%
Garbers et al17 2013 Retrospective
cohort
14e19 73 Cu-IUD 6 6 mo Continuation NR US NR 15%
Aoun et al16 2014 Retrospective
cohort
13e24 999 Cu-IUD
LNG-IUD
36 12 mo Continuation
Expulsion
NR US 16% 13%
Cohen et al22 2016 Prospective
cohort
13e22 244 Cu-IUD
LNG-IUD
Implant
12 12 mo Continuation
6 mo Continuation
Expulsion
Postpartum US 0 17%
Teal et al23 2015 Retrospective
cohort
13e24 1146 Cu-IUD
LNG-IUD
6 6 mo Continuation
Expulsion
Interval US 59% 30%
Berlan et al25 2016 Retrospective
cohort
12e22 750 Implant 12 12 mo Continuation Interval US 85% NR
Gemzell-Danielsson et al26 2016 Prospective
cohort
12e17 304 LNG-IUD 12 12 mo Continuation
AE
Interval Multi 98% 1%
Total N: 4886
AE, adverse events; Cu, copper-containing; IUD, intrauterine device; LARC, long-acting reversible contraceptive; LNG, levonorgestrel-containing; NR, not reported; RCT, randomized controlled trial.
Diedrich. LARCs and adolescents. Am J Obstet Gynecol 2017.
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studies. Data extracted included the
study methodology, number of partici-
pants, age range, type of LARC used,
and insertion setting (postpartum,
postabortion, or interval). Interval
insertion was defined as not during the
initial postpartum period. Additional
data extracted were the time of follow-
up, primary and secondary outcomes
measured, and attrition. We noted the
number (and ages) of adolescents
included, and their specific subgroup
outcomes. We also recorded the num-
ber of reported IUD expulsions.
Assessment of risk of bias
Risk of bias was assessed using the
checklist described by Downs and
Black.14 Studies received points for their
low risks of bias in several categories:
reporting, external validity, bias, and
confounding. There were a total of 27
points assigned in the following cate-
gories: reporting (10 points possible),
external validity (3 points possible), bias
(7 points possible), and confounding (7
points possible). Studies were grouped
according to their score, with high scores
indicating lower risk bias: excellent (25-
27), good (19-24), fair (14-18), and poor
(<14).
Data synthesis
The proportion of women continuing
LARC methods were pooled for contin-
uation rates of 6 and 12 months using a
random effects model. Individual esti-
mates were weighted by their SE. The
same technique was used for pro-
portions of women with expulsion of
their IUDs. Heterogeneity of studies was
assessed by using I2 and further charac-
terized using Egger test of publication
bias.
Results
Study selection
Using our search strategy, 1677 citations
were identified. From these titles and
abstracts, 90 articles appeared to meet
our inclusion criteria. Of these, 39 were
excluded because they did not provide
data on the primary endpoint; 24 were
excluded because the primary endpoint
was not stated for the adolescent sub-
group; 8 studies were separate analyses of
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other included studies; 4 were excluded
because follow-up was <70%; and an
additional 3 studies were excluded
because they were cross-sectional
studies. After exclusions, 12 articles
that met all criteria and were included
for analysis.15-26 Figure 1 shows the
selection of included articles.
Study characteristics
Characteristics of individual studies
are presented in Table 1. A total of
4886 adolescent and young adult
women (<25 years of age) were
included from all studies. Sample sizes
from the included studies ranged from
23-1146. Among the included studies,
755 subjects used the subdermal
implant and 4131 used the IUD. There
were 8 studies that included the Cu-
IUD,15-18,20-23 9 studies that included
the LNG-IUD,15-18,20-23,26 and 4
studies that included the ENG
implant.19,22,25,27 Many of the studies
compared LARC methods. Compari-
sons between Cu-IUD and LNG-IUD
were performed in 8 studies15-18,20-23;
2 studies included cohorts of both
IUD and the ENG implant users.20,22
Three studies included only data for
6 months of continuation,17,18,23
which account for a total of 1242 pa-
tients. LARCs were placed postpartum
in 4 studies,19,21,22,24 and interval
placement in 3 studies.15,18,23 There
were 2 studies16,17 that did not specify
the timing of LARC placement. One
study20 allowed placement post-
partum, postabortion, or interval.
Of the 12 studies, 1 study was a RCT,18
and the remaining 11 were obser-
vational studies. Five studies were pro-
spective cohort studies19-21,26,27 and 6
studies were retrospective cohort
studies.15-17,21,23,25 Overall, approxi-
mately 34% of adolescents in the
included studies were nulliparous.
Follow-up ranged between 6-96 months,
with median follow-up of 12 months.
Median follow-up was the same for
both prospective and retrospective
studies. Ten of the included studies
were performed in the United
States,15-18,20-23,25-27 1 study was
FIGURE 2
Pooled 12-month continuation rates of long-acting reversible contraceptive (LARC) methods among adolescents
ID, identification of study; ES, effect size; CI, confidence interval; LARC, long-acting reversible contraceptive.
Diedrich. LARCs and adolescents. Am J Obstet Gynecol 2017.
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performed in Brazil,19 and 1 study was a
multinational study.26
Randomized controlled trial
Godfrey and colleagues18 performed a
pilot RCT that randomized 23 adoles-
cents and young women between age
13-18 years to either Cu-IUD (n ¼ 11)
or LNG-IUD (n ¼ 12). Subjects had an
interval IUD placement or placement at
least 7 weeks postpartum. Continuation
at 6 months was 75% for LNG-IUD
and 45% for Cu-IUD (P ¼ .15).
Despite high discontinuation, the ma-
jority of subjects reported being satis-
fied with their IUD at 6 months (70%
of LNG-IUD and 80% of Cu-IUD
users). Two Cu-IUD expulsions, but
no LNG-IUD expulsions, were
reported.
Observational studies
In 2012, Rosenstock and colleagues20
published a subanalysis of the adoles-
cents participating in the Contraceptive
CHOICE Project. CHOICE was a pro-
spective observational study of women
in the St Louis, MO, area who were
provided with no-cost contraception for
2-3 years. All participants received tier-
based contraceptive counseling and
their method of choice. Of the 763 ad-
olescents and young women (14-19
years) who started a LARC method at
baseline, continuation at 12 months was
81% among LNG-IUD users, 76%
among Cu-IUD users, and 82% among
implant users. By 12 months, <6% of
adolescent participants had been lost to
follow-up. Expulsion of IUDs was not
reported in the article. However, another
article from the same study population
estimated the risk of expulsion at 10.5
per 100 IUD users per 12 months (95%
confidence interval [CI], 8.0e13.5)
among women <20 years of age.28
Guazzelli and colleagues19 included 44
adolescents who presented <6 months
postpartum for LARC at a clinic in São
Paolo, Brazil. The cohort had an average
age of 17 years; 91% had 1 child and the
remainder had 2. All women included
had a subdermal implant placed and
were followed prospectively for 1 year;
6% were lost to follow-up. Continuation
was 94% at 12 months, and the rate of
amenorrhea was 38% by 12 months.
Another prospective study was per-
formed by Cohen and colleagues.22 Ad-
olescents and young women (ages 13-22
years) who chose postplacental IUDs
FIGURE 3
Pooled 12-month continuation rates of intrauterine devices (IUD) among adolescents
ID, identification of study; ES, effect size; CI, confidence interval; IUD, intrauterine device.
Diedrich. LARCs and adolescents. Am J Obstet Gynecol 2017.
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(n ¼ 82) or subdermal implant (n ¼
162) to be placed prior to discharge were
included. At 12 months, IUD continua-
tion was 62% and implant continuation
was 72%. The observed IUD expulsion
rate reported was 21%.
Tocce and colleagues24 performed a
prospective cohort study of 171 post-
partum adolescents and young women
(ages 13-24 years) who had subdermal
implant placed prior to discharge. This
group was compared to a control group
of adolescents who chose any other
method. The primary outcomes were
contraceptive continuation and repeat
pregnancy rates. Continuation of the
implant was 97% at 6 months and 86%
at 12 months. The odds of pregnancy
were 8 times higher for those who did
not choose immediate postpartum
implant (odds ratio, 8.0; 95% CI,
2.8e23.0) compared to women who did
choose insertion.
In a subgroup analysis of a large
multinational prospective phase III trial,
Gemzell-Danielsson and colleagues26
evaluated the use of a new IUD among
girls and adolescents (12-17 years of
age). The IUD evaluated was a LNG-IUD
containing 13.5 mg of levonorgestrel
released at a rate of 8 mg/d. There were
304 adolescents who had the LNG-IUD
inserted, and all were followed up for
12 months. Continuation at 12 months
was 83%. There were 10 expulsions (3%)
during 12 months.
In a retrospective cohort study, Alton
and colleagues15 identified 233 adoles-
cents age <21 years who had each
received a Cu-IUD (n ¼ 11) or LNG-
IUD (n ¼ 222) during an 8-year
period. The IUDs had been placed at a
private faculty clinic or at a hospital-
based Title X clinic. Of their study pop-
ulation, 70% were parous and the me-
dian age at insertion was 16 years. At 12
months, continuation was 70% among
the youngest group of adolescents (age
<18 years) and 89% among those age
18-21 years. The number of IUD ex-
pulsions was not reported.
Teal and Sheeder21 performed a
retrospective cohort study of parous
adolescents and young women (14-23
years of age) who had each received a
LNG-IUD or Cu-IUD. The average
insertion time was 8months postpartum
(none were placed immediately after
placental delivery).Median continuation
of IUDuse was 14months; range was not
FIGURE 4
Pooled 12-month continuation rates of etonogestrel (ENG) subdermal implants among adolescents
ID, identification of study; ES, effect size; CI, confidence interval; ENG, etonogestrel subdermal implant.
Diedrich. LARCs and adolescents. Am J Obstet Gynecol 2017.
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reported. There was no difference in
continuation based on type of IUD.
Continuation rates were censored at 60
months. Twelve-month continuation
was 55%, and an expulsion rate of 15%
was observed.
Garbers and colleagues17 retro-
spectively reviewed charts of 73 ado-
lescents and young women (ages
14-19 years) who had sought family
planning services and had Cu-IUDs
placed. According to chart review,
6-month continuation of the Cu-IUD
was 88%. IUD expulsions were not
reported.
Aoun and colleagues16 reviewed
charts of 999 adolescents and young
women (age 14-24 years) who received a
Cu-IUD or LNG-IUD. At the time of
insertion, approximately 16% of
participants were nulliparous. At 12
months, continuation was 80%. Only
13% were lost to follow-up. An expul-
sion rate of 4% was observed.
Teal and colleagues23 performed a
retrospective study of adolescents and
young women (13-24 years) who desired
an IUD. The goal of this study was to
quantify complications and unsuccessful
insertions among 1177 who had an
attempted IUD placement. Among the
1146 who had a successful insertion,
continuation of the IUD was 95% at 6
months. A 2% IUD expulsion rate was
observed.
A retrospective study was performed
by Berlan and colleagues25 evaluating 12-
month continuation of the subdermal
implant by adolescents 12-22 years of
age. The majority (85%) were
nulliparous. Of 750 patients who had the
device placed, only 10% had dis-
continued by 12 months (90%
continuation).
Assessment of risk of bias
The majority of the included studies
were of fair or good quality under the
Downs and Black methodology. Overall,
the average score for reporting results
was 9 of 10 points; average scores for
external validity were 2.25 of 3 points;
average scores for bias were 4 of 7 points;
and the average score for confounding
was 2.4 of 7 points. See Table 2 for re-
sults. The majority of studies had low
scores for confounding and bias, which
mainly is due to study design. Because
only 1 study included was a RCT, there is
a higher risk of bias among the
FIGURE 5
Pooled postpartum 12-month continuation rates of long-acting reversible contraceptive (LARC) devices
ID, identification of study; ES, effect size; CI, confidence interval; LARC, long-acting reversible contraceptive.
Diedrich. LARCs and adolescents. Am J Obstet Gynecol 2017.
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remaining studies. However, 1 advantage
of a meta-analysis of observational
studies is generalizability and obtaining
estimates that are closer to real-life
continuation. In practice, women are
able to choose their contraceptive
method and are not randomly assigned
one.
Data synthesis
The 12-month continuation rates of all
LARC methods are provided in Figure 2.
Continuation was 84.0% (95% CI,
79.0e89.0%) for all LARC methods
combined. The 12-month continuation
rate for IUDs is shown in Figure 3. At 12
months, IUD continuation was 74.0%
(95% CI, 61.0e87.0%). The 12-month
continuation of ENG implant 84%
(95% CI, 77.0e91.0%) is shown in
Figure 4. Figure 5 shows 12-month
continuation when LARC devices were
placed in the postpartum setting. At
12 months, continuation was 84.0%
(95% CI, 71.0e97.0%). IUD expulsion
rates were pooled in Figure 6, and the
overall effect was an expulsion rate of
8.0% (95% CI, 4.0e11.0%). There is
significant heterogeneity among studies
in all the comparisons above (I2 > 92%,
P < .001).
Comment
Main findings
This systematic review and meta-
analysis demonstrates that adolescent
continuation of LARCmethods is high at
12 months. This includes parous
adolescents who had devices placed
postpartum as well as nulliparous ado-
lescents. These findings support the
recommendations of the ACOG8 as well
as the AAP,9 which encourages adoles-
cents to consider LARC methods. The
CDC also recommends using the
methods most effective and medically
appropriate for adolescents, including
LARC methods.29
Strengths and limitations
One strength of this review is its
estimates of continuation among the
different studies reviewed. Additionally,
the pooled continuation rate includes a
large sample. By including observational
trials in addition to RCT, we are able to
estimate real-world continuation of
FIGURE 6
Pooled intrauterine device (IUD) expulsion rates among adolescents
ID, identification of study; ES, effect size; CI, confidence interval; IUD, intrauterine device.
Diedrich. LARCs and adolescents. Am J Obstet Gynecol 2017.
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LARCs more accurately (increased
generalizability). In actual practice, pa-
tients are given a choice of contraceptive
method and must choose what they
think best fits their priorities and life-
styles. Meta-analyses that include only
RCT may actually introduce selection
bias by eliminating patient choice of
method.
A weakness of this review is the sig-
nificant heterogeneity among the indi-
vidual studies examined, which limits
the ability to combine continuation
outcomes. However, these studies are
representative of the variety of settings of
LARC provision. When assessing expul-
sions, there may be significant differ-
ences between Cu-IUD and LNG-IUD.
Additionally, 1 study26 assessed a lower-
dose LNG-IUD (13.5 mg reservoir,
releasing 8 mg/d), which should be
distinguished from the other LNG-IUDs
on the market in the United States.
Liletta (Medicines 360) and Mirena
(Bayer) contain 52 mg of levonorgestrel
and release 20 mg/d, Kyleena (Bayer)
contains 19.5 mg and releases 9 mg/d,
and Skyla (Bayer) contains 13 mg and
releases 8 mg/d. Another limitation may
be the inclusion of women up to 25 years
of age. This was done intentionally as
there is not an agreed-upon definition of
the exact years of adolescence. Addi-
tionally, not all studies presented data on
barriers to removal. When LARC
removal is not free or easily attainable for
participants, this may not only falsely
increase continuation, but in fact be
construed as coercive.
Comparison with existing literature
A Cochrane review by Krashin et al30
and systematic review by Deans and
Grimes31 and Usinger et al32 showed
adolescent continuation of 75-86%with
IUDs. However, these reviews included
only RCT, which are different from
most prospective observational trials in
that patients in observational trials
ordinarily are allowed choice of con-
traceptive method. Observational
studies may provide greater generaliz-
ability and a more realistic estimate of
continuation rates. RCT can lead to an
increased discontinuation because the
methods are assigned randomly.33,34
Another systematic review was per-
formed by Usinger et al32 included RCTs
as well as observational studies of
women under age 25 who received any
type of IUD. They excluded studies that
did not compare IUDs to other
methods. Our findings are also consis-
tent with a large retrospective study
including women in TRICARE. The
study includes women of all ages, but in
a multivariable analysis found that girls
and women 14-19 years of age had
higher continuation of LARC methods
when compared to women 35-40 years
of age: 1.34 (95% CI, 1.27e1.42). Data
were not listed for continuation by age
group at 12 months.35 Another large
retrospective study evaluated insurance
claims data of approximately 90,000
women who had an IUD placed from
2002 through 2009. Within this cohort
there were 1528 girls and women age
15-19 years who used the LNG-IUD and
307 in the same age group who used the
Cu-IUD. Among those 20-24 years of
age, 7860 and 2027 used the LNG-IUD
and Cu-IUD, respectively. In the
younger cohort the continuation rates
for LNG-IUD and Cu-IUD were 88.2%
and 79.8% at 12months, respectively. In
the cohort aged 20-24 years, continua-
tion was 87.7% and 84.1% for the LNG-
IUD and Cu-IUDs at 12 months,
respectively.36 The main limitation of
this type of study is the potential inac-
curacy of claims data.
Conclusion with implications
LARC continuation in adolescents and
young women is high. IUDs and im-
plants should be offered to all adolescents
as first-line contraceptive options as long
as device removal is readily available.
Efforts to increase the use of LARC will
help decrease the rates of unintended
adolescent pregnancy, abortion, and
unintended childbearing, and will
thereby also help lower the disparities in
those rates among different sociodemo-
graphic adolescent populations. -
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Ovid MEDLINE
1 exp contraception/or exp contra-
ceptive devices/or exp contraceptive
agents/
2 1 and LARC (tw)
3 “long acting reversible
contraception”.tw.
4 exp intrauterine devices/
5 exp drug implants/ and 1
6 etonogestrel implant: (tw)
7 levonorgestrel intrauterine system:
(tw)
8 2 or 3 or 4 or 5 or 6 or 7
9 limit 8 to English language
10 limit 9 to yr¼“2002 -Current”
11 limit 10 to “adolescent (13e18 years)”
12 limit 10 to “young adult (19e24
years)”
13 11 or 12
Reviews - Cochrane Database of
Systematic Reviews
1 “long acting reversible
contraception”.tw.
2 etonogestrel implant: (tw)
3 levonorgestrel intrauterine system:
(tw)
4 LARC.mp. [mp¼title, short title,
abstract, full text, keywords, caption
text]
5 1 or 2 or 3 or 4
6 from 5 keep 2, 9e11, 14e15, 20,
24e25
7 contracept: (tw)
8 (teen: or adolesce:) (tw)
9 7 and 8
10 from 9 keep 7, 13, 16, 23, 39, 60
11 6 or 10
Reviews - Cochrane Central Register of
Controlled Trials
1 (contraception or contraceptive).mp.
[mp¼title, original title, abstract,
mesh headings, heading words,
keyword]
2 (adolescent or young or nullipar-
ous).mp. [mp¼title, original title,
abstract, mesh headings, heading
words, keyword]
3 (continuation or discontinuation or
side effects or compliance or sat-
isfaction).mp. [mp¼title, original ti-
tle, abstract, mesh headings, heading
words, keyword]
4 1 and 2 and 3
5 limit 4 to yr¼“2002 -Current”
Embase -
(((contraception OR (contraceptive
device) OR (contraceptive agent))
AND LARC)
OR
(long acting reversible contraception)
OR (intrauterine device)
OR
(((contraception OR (contraceptive
device) OR (contraceptive agent))
AND (drug implant))
OR
(etonogestrel implant)
OR
(levonorgestrel intrauterine system)
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